# OnCo record profound (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/profound/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "profound", "NCT02987543" ;
  schema:name "PROfound"@en ;
  schema:description "The first biomarker-selected trial in prostate cancer to improve survival, using a PARP inhibitor in men with BRCA-type mutations."@en ;
  schema:url <https://onco.cc/trials/profound/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02987543>, <https://www.nice.org.uk/guidance/ta887> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2017-02-06" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/prostate-hrr-eligibility/>, <https://onco.cc/terms/prostate-uk-drug-approvals/> ;
  onco:trials <https://onco.cc/trials/triton3/>, <https://onco.cc/trials/propel/> ;
  onco:people <https://onco.cc/people/maha-hussain/>, <https://onco.cc/people/johann-de-bono/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-profound-nejm-2020/> .